Solid Tumor Testing Market Report 2024 (Global Edition)

Global Solid Tumor Testing Market Report 2024 Market Size Split by Type (Genetic Testing, Genetic Test Type, Next generation sequencing (NGS), Real-time PCR (RT-PCR), Fluorescent In-Situ Hybridization...

Solid Tumor Testing Market Report Description

We have various report editions of Solid Tumor Testing Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Solid Tumor Testing Market Insights Video

Competitive Landscape of the Solid Tumor Testing Market

The competitive landscape of the solid tumor testing market is characterized by a wide spectrum of participants competing to gain market share through product innovation, strategic partnerships, and aggressive marketing efforts. Key players in the market include established electronics manufacturers, specialized solid tumor testing companies, and emerging start-ups aiming to disrupt the market with creative techniques.

In September 2022, Seagen and LAVA Therapeutics declared a strategic collaboration to manufacture and commercialize LAVA-1223, an advanced epidermal expansion factor receptor that can efficiently detect solid tumors. (Source: https://ir.lavatherapeutics.com/news-releases/news-release-details/seagen-and-lava-therapeutics-announce-exclusive-worldwide#:~:text=News%20%26%20Events-,Seagen%20and%20LAVA%20Therapeutics%20Announce%20Exclusive%20Worldwide%20License%20Agreement%20to,for%20EGFR%2DExpressing%20Solid%20Tumors&text=BOTHELL%2C%20Wash.,GLOBE%20NEWSWIRE)%20%2D%2D%20Seagen%20Inc.)

Top Companies Market Share in Solid Tumor Testing Industry: (In no particular order of Rank)

• Abbott Laboratories
• Agilent Technologies
• Biocare Medical
• LLC.
• F. Hoffmann-La Roche Ltd
• Illumina
• Inc.
• MedGenome
• Myriad Genetics
• QIAGEN NV.
• Quest Diagnostics
• Thermo Fischer Scientific
• Inc.
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Solid Tumor Testing Market

Which Region Dominates the Solid Tumor Testing Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024 and accounted for around 40% of the global revenue due to high cancer prevalence, advanced healthcare infrastructure, and substantial investment in R&D. The region benefits from widespread adoption of personalized medicine, availability of advanced diagnostic technologies, and supportive government initiatives promoting cancer screening and early diagnosis.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the solid tumor testing market due to the region's rising cancer prevalence, increasing healthcare expenditure, and advancements in diagnostic technologies. Growing awareness of early detection, personalized medicine, and supportive government initiatives further propel market growth.

The current report Scope analyzes Solid Tumor Testing Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Solid Tumor Testing Market

According to Cognitive Market Research, the global solid tumor testing market size was estimated at USD 24514.2 Million, out of which North America held the major market of more than 40% of the global revenue with a market size of USD 9805.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the solid tumor testing market with a market size of USD 7736.68 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The nation's high burden of breast cancer drives market.
• The Canadian solid tumor testing market had a market share of USD 1176.8 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. Canada's strategic initiatives by market players.
• The Mexico solid tumor testing market is projected to witness growth at a CAGR of 6.7% during the forecast period, with a market size of USD 892.32 million in 2024.

Europe Solid Tumor Testing Market

According to Cognitive Market Research, the global solid tumor testing market size was estimated at USD 24514.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 7354.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

• The United Kingdom's solid tumor testing market had a market share of USD 1235.52 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. In the UK, solid tumor testing sales witness an upswing due to the nation's rise in the number of people suffering from cancer.
• The France solid tumor testing market is projected to witness growth at a CAGR of 5.7% during the forecast period, with a market size of USD 676.59 million in 2024.
• According to Cognitive Market Research, the German solid tumor testing market size was valued at USD 1456.14 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. In Germany, solid tumor testing sales surged due to the high utilization of spatial techniques for cancer research.
• The Italy solid tumor testing market is projected to witness growth at a CAGR of 5.9% during the forecast period, with a market size of USD 632.47 million in 2024.
• The Russian solid tumor testing market is projected to witness growth at a CAGR of 5.5% during the forecast period, with a market size of USD 1139.91 million in 2024.
• The Spain solid tumor testing market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD 603.05 million in 2024
• The Luxembourg solid tumor testing market is projected to witness growth at a CAGR of 6.6% during the forecast period, with a market size of USD 227.98 million in 2024.
• The Portugal solid tumor testing market is projected to witness growth at a CAGR of 6.3% during the forecast period, with a market size of USD 154.44 million in 2024.
• The Greece solid tumor testing market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 88.25 million in 2024.
• Rest of Europe's solid tumor testing market is projected to witness growth at a CAGR of 5.2% during the forecast period, with a market size of USD 1139.91 million in 2024.

Asia Pacific Solid Tumor Testing Market

According to Cognitive Market Research, the global solid tumor testing market size was estimated at USD 24514.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 5638.27 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• According to Cognitive Market Research, the China solid tumor testing market size was valued at USD 2537.22 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. Solid tumor testing sales surged in China due to advancements in the oncology department.
• The Japan solid tumor testing market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 778.08 million in 2024.
• The India solid tumor testing market had a market share of USD 676.59 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. India's government initiatives augment the demand.
• The South Korean solid tumor testing market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 563.83 million in 2024.
• The Australian solid tumor testing market is projected to witness growth at a CAGR of 9.7% during the forecast period, with a market size of USD 293.19 million in 2024.
• The South East Asia solid tumor testing market is projected to witness growth at a CAGR of 11.0% during the forecast period, with a market size of USD 389.04 million in 2024.
• The Rest of the Asia Pacific Solid Tumor Testing market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 400.32 million in 2024.

South America Solid Tumor Testing Market

According to Cognitive Market Research, the global solid tumor testing market size was estimated at USD 24514.2 Million, out of which Latin America market of more than 5% of the global revenue with a market size of USD 1225.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil solid tumor testing market size was valued at USD 524.60 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. Solid tumor testing sales flourish in Brazil due to the rising advancement in technology.
• Argentina's solid tumor testing market had a market share of USD 205.92 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. The demand is augmented by Argentina's stringent environmental regulations.
• Colombia's solid tumor testing market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 109.09 million in 2024.
• Peru solid tumor testing market is projected to witness growth at a CAGR of 7.6% during the forecast period, with a market size of USD 100.51 million in 2024.
• Chile solid tumor testing market is projected to witness growth at a CAGR of 7.7% during the forecast period, with a market size of USD 88.25 million in 2024.
• The Rest of Latin America's solid tumor testing market is projected to witness growth at a CAGR of 6.5% during the forecast period, with a market size of USD 197.32 million in 2024.

Middle East and Africa Solid Tumor Testing Market

According to Cognitive Market Research, the global solid tumor testing market size was estimated at USD 24514.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 490.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.

• The GCC Countries' solid tumor testing market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 209.84 million in 2024. Solid tumor testing sales flourish due to the presence of major market players.
• Egypt solid tumor testing market is projected to witness growth at a CAGR of 8.0% during the forecast period with a market size of USD 51.48 million in 2024.
• The South African solid tumor testing market is projected to witness growth at a CAGR of 8.7% during the forecast period, with a market size of USD 77.46 million in 2024. Solid tumor testing sales flourished in South Africa due to the increasing healthcare infrastructure.
• The Turkey solid tumor testing market is projected to witness growth at a CAGR of 7.2% during the forecast period, with a market size of USD 42.16 million in 2024.
• The Nigeria solid tumor testing market is projected to witness growth at a CAGR of 6.8% during the forecast period, with a market size of USD 51.48 million in 2024.
• The Rest of MEA solid tumor testing market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 57.85 million in 2024.

Solid Tumor Testing Market Analysis

Solid Tumor Testing Market Type Segment Analysis

According to Cognitive Market Research, genetic testing are the dominating category due to the technological advancements in sequencing and diagnostics, and the increasing adoption of personalized medicine. Enhanced awareness and demand for early, precise cancer detection and treatment options, along with supportive government initiatives and expanding healthcare infrastructure, further propel market growth.

Real-time PCR (RT-PCR) emerged as the fastest-growing category over the projected period due to its ability to provide accurate results swiftly and aid in personalized treatment decisions, improving patient outcomes. RT-PCR's versatility and reliability make it a cornerstone technology in advancing precision oncology diagnostics.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Solid Tumor Testing Industry. Request a Free Sample PDF!

Application Segment Analysis

According to Cognitive Market Research, the dominating category is prostate due to advancements in diagnostic technologies like PSA testing and genomic profiling and growing demand for personalized treatment options. Rising awareness among men about early detection and treatment, coupled with healthcare infrastructure improvements, propel market growth.

The fastest-growing category in the solid tumor testing market is breast over the projected period due to increasing incidences of breast cancer, advancements in genetic testing technologies like next-generation sequencing (NGS) and immunohistochemistry (IHC), and rising demand for personalized treatment options.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Solid Tumor Testing End-User Segment Analysis

End User Segment Analysis

According to Cognitive Market Research, the dominating category is pharmaceutical and biotechnology companies due to the development of advanced testing technologies like Next-Generation Sequencing (NGS) and targeted therapies that enhance personalized treatment options. This proactive approach enables more accurate diagnosis, prognosis, and therapeutic selection, ultimately improving patient outcomes in oncology.

The fastest-growing category in the solid tumor testing market is hospitals over the projected period due to the adoption of advanced testing technologies, such as NGS and liquid biopsy, enhancing patient care and outcomes. Hospitals' ability to integrate these innovations into clinical practice accelerates personalized medicine, improving precision in cancer diagnosis and treatment selection.

• Hospitals
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutions

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion